| Verbrec Limited (VBC) ORDINARY FULLY PAID |
Industrials |
$20 |
H1 FY2025 - Interim Financial Report
|
27 Feb 2025 5:09PM |
$0.125 |
$0.068 |
fallen by
45.60%
|
|
| Integral Diagnostics Limited (IDX) ORDINARY FULLY PAID |
Health Care |
$849 |
Update - Dividend/Distribution - IDX
|
27 Feb 2025 5:08PM |
$2.360 |
$2.280 |
fallen by
3.39%
|
|
| BetaShares Western Asset Australian Bond Fund (Managed Fund) (BNDS) |
Financials |
$832 |
Estimated Distribution Announcement
|
27 Feb 2025 5:08PM |
$23.670 |
$23.930 |
risen by
1.10%
|
|
| Shriro Holdings Limited (SHM) ORDINARY FULLY PAID |
Consumer Discretionary |
$53 |
Market Update Feb 2025
|
27 Feb 2025 5:07PM |
$0.800 |
$0.680 |
fallen by
15%
|
|
| Verbrec Limited (VBC) ORDINARY FULLY PAID |
Industrials |
$20 |
H1 FY2025 - Appendix 4D
|
27 Feb 2025 5:04PM |
$0.125 |
$0.068 |
fallen by
45.60%
|
|
VBC - Price-sensitive ASX Announcement
Full Release
Key Points
- Half Year Report for Verbrec Limited for the period ended 31 December 2024.
- Revenue from continuing operations decreased by 14.4% to $42.814 million.
- Profit from continuing operations after tax attributable to members fell by 69.8% to $861,000.
- Net profit for the period increased by 338.1% to $793,000.
- No dividends were proposed for payment during the current or previous period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tartana Minerals Limited (TAT) ORDINARY FULLY PAID |
Materials |
$9 |
Notification regarding unquoted securities - TAT
|
27 Feb 2025 5:03PM |
$0.043 |
$0.042 |
fallen by
2.33%
|
|
| Shriro Holdings Limited (SHM) ORDINARY FULLY PAID |
Consumer Discretionary |
$53 |
Dividend/Distribution - SHM
|
27 Feb 2025 5:01PM |
$0.800 |
$0.680 |
fallen by
15%
|
|
| Shriro Holdings Limited (SHM) ORDINARY FULLY PAID |
Consumer Discretionary |
$53 |
Half Yearly Report and Accounts
|
27 Feb 2025 5:00PM |
$0.800 |
$0.680 |
fallen by
15%
|
|
SHM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased to $55.9 million, down 12.9% from the previous year.
- EBITDA increased by 3.8% to $10.8 million.
- Operating expenses reduced by 20.2% due to business restructuring.
- Net cash stands at $24.7 million.
- Dividend of 2.0 cents per share declared for the half year.
- Company focused on growth through product development and geographic expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kula Gold Limited (KGD) ORDINARY FULLY PAID |
Materials |
$6 |
Notification regarding unquoted securities - KGD
|
27 Feb 2025 4:58PM |
$0.005 |
$0.007 |
risen by
40%
|
|
| Kula Gold Limited (KGD) ORDINARY FULLY PAID |
Materials |
$6 |
Notification regarding unquoted securities - KGD
|
27 Feb 2025 4:57PM |
$0.005 |
$0.007 |
risen by
40%
|
|
| Beacon Minerals Limited (BCN) ORDINARY FULLY PAID |
Materials |
$127 |
Appendix 4D and 2024 Half Year Financial Report
|
27 Feb 2025 4:57PM |
$0.025 |
$0.030 |
risen by
20%
|
|
BCN - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for the half-year was $41,048,563.
- The company reported a loss from ordinary activities after tax of $7,280,066.
- Gold sales totaled 10,927 ounces at an average price of $3,914 per ounce.
- Operational highlights include 12,091 ounces of gold produced.
- The Iguana Deposit at Lady Ida has a mineral resource estimate of 609,000 ounces.
- Completed a $10.3 million entitlement issue fully underwritten.
- Exploration activities focused on the Tycho and MacPherson leases.
- Joint venture agreement for Lady Ida Project executed.
- No dividends declared for the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kula Gold Limited (KGD) ORDINARY FULLY PAID |
Materials |
$6 |
Application for quotation of securities - KGD
|
27 Feb 2025 4:56PM |
$0.005 |
$0.007 |
risen by
40%
|
|
| Asara Resources Limited (AS1) ORDINARY FULLY PAID |
Materials |
$59 |
Becoming a substantial holder
|
27 Feb 2025 4:56PM |
$0.034 |
$0.054 |
risen by
58.82%
|
|
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$425 |
LDA Capital Call Notice
|
27 Feb 2025 4:55PM |
$0.258 |
$0.210 |
fallen by
18.45%
|
|
BRN - Price-sensitive ASX Announcement
Full Release
Key Points
- BrainChip issues Capital Call Notice to LDA Capital to sell up to 40,000,000 shares
- Available funding under the LDA Agreement stands at AUD $74.8M
- Company commences search for a Senior Operations Manager to support its operations
- Company obligated to advance a minimum of 40 million shares to LDA by June 30, 2025
- Issue price of shares will be 91.5% of the higher daily volume weighted average price
- Company intends to use capital to execute on product roadmap and development initiatives
- Significant expansion of the Company’s portfolio of proprietary TENNs based models underway
- Enhancements to the Akida 2.0 platform aimed at a release in the second half of 2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID |
Health Care |
$29 |
Appendix 4D and Half Yearly Accounts
|
27 Feb 2025 4:53PM |
$0.505 |
$0.350 |
fallen by
30.69%
|
|
COV - Price-sensitive ASX Announcement
Full Release
Key Points
- Cleo Diagnostics is developing a blood test for early ovarian cancer diagnosis.
- The test utilizes a patented CXCL10 biomarker.
- Clinical trials have commenced in the U.S. and Australia.
- FDA-enabling trials involve patient recruitment of at least 500 individuals.
- The company plans to submit its application to the FDA by the end of 2025.
- Cleo's financial loss decreased to $1,950,364 for the half-year ended December 2024.
- Cash reserves at the end of the reporting period amounted to $7.311M.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cadence Opportunities Fund Limited (CDO) ORDINARY FULLY PAID |
Financials |
$27 |
Media Release - Half Year Results
|
27 Feb 2025 4:50PM |
$1.700 |
$1.680 |
fallen by
1.18%
|
|
CDO - Price-sensitive ASX Announcement
Full Release
Key Points
- Half-year loss after tax of $0.3 million.
- Portfolio down 1.1% over six months.
- Top performance contributors included Echo IQ, Netflix, and Iperionx.
- Major detractors included Whitehaven Coal and BHP.
- Downturn in commodity prices adversely affected investment performance.
- Positive returns from Netflix and Meta Platforms due to turnaround strategies.
- Participation in Echo IQ equity raise provided excellent returns.
- 6.5 cent fully franked interim dividend declared.
- Annualised yield of 7.6% fully franked.
- CDO trading at a 12% discount to NTA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$425 |
BrainChip Evaluates Redomiciling to US
|
27 Feb 2025 4:50PM |
$0.258 |
$0.210 |
fallen by
18.45%
|
|
BRN - Price-sensitive ASX Announcement
Full Release
Key Points
- BrainChip to investigate redomiciling to the US in 2025
- Decision made after extensive strategic review by the Board
- Aim to list on a US-based securities exchange
- Existing shareholders to hold equivalent US-listed securities
- US market provides a larger and more technologically savvy investor base
- Potential for positive re-evaluation and re-pricing of shares
- SEC rules offer greater protection for sensitive information
- Delisting from ASX to reduce regulatory compliance and costs
- Chairman believes decision is in the best interest of all stakeholders
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cadence Opportunities Fund Limited (CDO) ORDINARY FULLY PAID |
Financials |
$27 |
Dividend/Distribution - CDO
|
27 Feb 2025 4:45PM |
$1.700 |
$1.680 |
fallen by
1.18%
|
|
| Sims Limited (SGM) ORDINARY FULLY PAID |
Materials |
$2,987 |
Change in substantial holding
|
27 Feb 2025 4:44PM |
$14.720 |
$15.460 |
risen by
5.03%
|
|
| Asara Resources Limited (AS1) ORDINARY FULLY PAID |
Materials |
$59 |
Change in substantial holding
|
27 Feb 2025 4:42PM |
$0.034 |
$0.054 |
risen by
58.82%
|
|
| Asara Resources Limited (AS1) ORDINARY FULLY PAID |
Materials |
$59 |
Change in substantial holding
|
27 Feb 2025 4:41PM |
$0.034 |
$0.054 |
risen by
58.82%
|
|
| Cadence Opportunities Fund Limited (CDO) ORDINARY FULLY PAID |
Financials |
$27 |
Appendix 4D Half Year Report 31 December 2024
|
27 Feb 2025 4:39PM |
$1.700 |
$1.680 |
fallen by
1.18%
|
|
CDO - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating loss before tax of $488,824
- Operating loss after tax of $271,542
- Gross performance of -1.1%
- Net investments valued at $27,630,291
- Net asset value decreased to $31,587,302
- Declared interim dividend of 6.5 cents per share
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tissue Repair Ltd (TRP) ORDINARY FULLY PAID |
Health Care |
$10 |
Appendix 4D and Half Year Report to 31 December 2024
|
27 Feb 2025 4:37PM |
$0.270 |
$0.170 |
fallen by
37.04%
|
|
TRP - Price-sensitive ASX Announcement
Full Release
Key Points
- Tissue Repair is a clinical stage biopharmaceutical company developing advanced wound healing products.
- The Group recorded a loss of $2,560,868 for the six months ending 31 December 2024.
- TR987® for treatment of chronic wounds has entered Phase 3 trials in the US.
- TR Pro+® sales increased by 35% in Q4 2024, with monthly sales peaking at $45k.
- The company is in advanced discussions for distribution partnerships in Australia and New Zealand.
- A total of more than 30 clinical sites have been identified across the US and Australia for TR987® trials.
- The FDA has been approached for a reclassification of TR987® as a biological product.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nagambie Resources Limited (NAG) ORDINARY FULLY PAID |
Materials |
$13 |
Production Target Retraction and Replacement Announcement
|
27 Feb 2025 4:36PM |
$0.017 |
$0.016 |
fallen by
5.88%
|
|
NAG - Price-sensitive ASX Announcement
Full Release
Key Points
- Nagambie Resources Limited is retracting the previously announced production target.
- The production target had not been disclosed in compliance with ASX Listing Rule 5.16.
- The production target was described as conceptual and its feasibility is currently unknown.
- New drilling results indicate high-grade antimony-gold intersections.
- The company reaffirmed that all material assumptions underpinning the current JORC Mineral Resource Estimation (MRE) remain valid.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| St George Mining Limited (SGQ) ORDINARY FULLY PAID |
Materials |
$86 |
Change of Director's Interest Notice x3
|
27 Feb 2025 4:35PM |
$0.021 |
$0.032 |
risen by
52.38%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
